✦ LIBER ✦

PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE

✍ Scribed by M Gyldmark; R Aultman; U Siebert; E Sabate

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and Cost Effectiveness of Bevac

✍ Eui-Kyung Lee; Cedric Revil; Charles A. Ngoh; Johanna Lister; Jeong-Mi Kwon; Mee 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 460 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

✍ Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Vehling-Kaiser, U.; Jage 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 225 KB

A retrospective observational study on t

✍ López, R; Salgado, M; Reboredo, M; Grande, C; Méndez, J C; Jorge, M; Romero, C; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 320 KB

First-line sunitinib plus FOLFIRI in Jap

✍ Yasushi Tsuji; Taroh Satoh; Akihito Tsuji; Kei Muro; Motoki Yoshida; Tomohiro Ni 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

PCN70 MODELLING THE COST EFFECTIVENESS O

✍ C Holmberg; R Aultman; U Siebert; E Sabate; M Gyldmark 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Bevacizumab in Combination With Chemothe

✍ Howard S. Hochster 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 352 KB